4.4 Article

Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma

期刊

GENES CHROMOSOMES & CANCER
卷 58, 期 8, 页码 558-566

出版社

WILEY
DOI: 10.1002/gcc.22737

关键词

papillary thyroid carcinoma; rearrangement; RNA-Seq; transcript fusion

资金

  1. Slaska BIO-FARMA. Centrum Biotechnologii, Bioinzynierii i Bioinformatyki [POIG.02.01.00-00-166/08]
  2. Polish National Center of Research and Development [STRATEGMED2/267398/4/NCBR/2015]
  3. PL-Grid Infrastructure
  4. Polish National Science Center [DEC-2011/03/N/NZ2/03495]

向作者/读者索取更多资源

Papillary thyroid carcinoma (PTC) is most common among all thyroid cancers. Multiple genomic alterations occur in PTC, and gene rearrangements are one of them. Here we screened 14 tumors for novel fusion transcripts by RNA-Seq. Two samples harboring RET/PTC1 and RET/PTC3 rearrangements were positive controls whereas the remaining ones were negative regarding the common PTC alterations. We used Sanger sequencing to validate potential fusions. We detected 2 novel potentially oncogenic transcript fusions: TG-FGFR1 and TRIM33-NTRK1. We detected 4 novel fusion transcripts of unknown significance accompanying the TRIM33-NTRK1 fusion: ZSWIM5-TP53BP2, TAF4B-WDR1, ABI2-MTA3, and ARID1B-PSMA1. Apart from confirming the presence of RET/PTC1 and RET/PTC3 in positive control samples, we also detected known oncogenic fusion transcripts in remaining samples: TFG-NTRK1, ETV6-NTRK3, MKRN1-BRAF, EML4-ALK, and novel isoform of CCDC6-RET.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据